Chemistry:Oxycodegol
From HandWiki
| |
| Names | |
|---|---|
| IUPAC name
(4R,4aS,7S,7aR,12bS)-9-methoxy-7-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-methyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-ol
| |
| Other names
Loxicodegol; NKTR-181
| |
| Identifiers | |
3D model (JSmol)
|
|
| DrugBank | |
| KEGG | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C31H49NO10 | |
| Molar mass | 595.730 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Oxycodegol (also known as loxicodegol and NKTR-181) is an experimental μ-opioid receptor agonist for the treatment of pain.[1][2] It has had success for back pain as an alternative to traditional opioids,[3] which have potential for abuse. It acts more slowly on the central nervous system, reducing risk for abuse and respiratory depression.[1]
References
- ↑ 1.0 1.1 Advokat, Claire D.; Comaty, Joseph E.; Julien, Robert M. (2019). Julien's Primer of Drug Action: a comprehensive guide to the actions, uses, and side effects of psychoactive drugs. New York: Worth Publishers. p. 565. ISBN 978-1-319-20054-1.
- ↑ "NKTR-181 (Oxycodegol) Oral Tablets for. Chronic Low Back Pain". https://www.fda.gov/media/134084/download.
- ↑ Markman, John; Gudin, Jeffrey; Rauck, Richard; Argoff, Charles; Rowbotham, Matthew; Agaiby, Eva; Gimbel, Joseph; Katz, Nathaniel et al. (June 2019). "SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain". PAIN 160 (6): 1374–1382. doi:10.1097/j.pain.0000000000001517. PMID 30747908.
 |  |
